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SignalingExogenous brain-derived neurotrophic factor (BDNF) enhances Ca2+ signaling and cell proliferation in human
airway smooth muscle (ASM), especially with inﬂammation. Human ASM also expresses BDNF, raising the po-
tential for autocrine/paracrine effects. The mechanisms by which ASM BDNF secretion occurs are not known.
Transient receptor potential channels (TRPCs) regulate a variety of intracellular processes including store-
operated Ca2+ entry (SOCE; including inASM) and secretion of factors such as cytokines. In humanASM,we test-
ed the hypothesis that TRPC3 regulates BDNF secretion. At baseline, intracellular BDNF was present, and BDNF
secretion was detectable by enzyme linked immunosorbent assay (ELISA) of cell supernatants or by real-time
ﬂuorescence imaging of cells transfected with GFP–BDNF vector. Exposure to the pro-inﬂammatory cytokine
tumor necrosis factor-alpha (TNFα) (20 ng/ml, 48 h) or a mixture of allergens (ovalbumin, house dust mite,
Alternaria, and Aspergillus extracts) signiﬁcantly enhanced BDNF secretion and increased TRPC3 expression.
TRPC3 knockdown (siRNA or inhibitor Pyr3; 10 μM) blunted BDNF secretion, and prevented inﬂammation
effects. Chelation of extracellular Ca2+ (EGTA; 1 mM) or intracellular Ca2+ (BAPTA; 5 μM) signiﬁcantly reduced
secreted BDNF, as did the knockdown of SOCE proteins STIM1 and Orai1 or plasma membrane caveolin-1. Func-
tionally, secreted BDNF had autocrine effects suggested by phosphorylation of high-afﬁnity tropomyosin-related
kinase TrkB receptor, prevented by chelating extracellular BDNF with chimeric TrkB-Fc. These data emphasize
the role of TRPC3 and Ca2+ inﬂux in the regulation of BDNF secretion by human ASM and the enhancing effects
of inﬂammation. Given the BDNF effects on Ca2+ and cell proliferation, BDNF secretionmay contribute to altered
airway structure and function in diseases such as asthma.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Primarily recognized and described in the nervous system,
neurotrophins (NTs) are growth factors important for neuronal devel-
opment and function [1–3]. There is now increasing evidence that NTs
and their receptors are expressed in non-neuronal tissues including
the airway [4–9], but their function is under investigation.We previous-
ly reported that brain-derived neurotrophic factor (BDNF), and its high-hial alveolar lavage; BAPTA, 1,2-
NF, brain-derived neurotrophic
rbent assay; GFP, green ﬂuores-
est; siRNA, small interference ri-
1, stromal interactive molecule
lpha; TrkB, tropomyosin-related
nic, Rochester, MN 55905, USA.
ights reserved.afﬁnity tropomyosin-related kinase (TrkB) as well as low-afﬁnity pan-
NT p75NTR receptors are expressed by human airway smooth muscle
(ASM) [6,7], and that exogenous BDNF enhances [Ca2+]i responses to
agonist [7] and cell proliferation [10]. Furthermore BDNF potentiates
the effects of pro-inﬂammatory cytokines such as tumor necrosis factor
(TNFα) [6,10,11].While these effects of exogenous BDNF are clearly rel-
evant to inﬂammatory airway diseases such as asthma, characterized by
enhanced airway contractility, ASM cell proliferation and remodeling,
the sources and mechanisms of regulation of BDNF in the airway are
not clear.
The classic understanding is that NTs such as nerve growth factor
(NGF) and BDNF are secreted from nerve endings and activate both
Trk and p75NTR receptors, leading to altered cell growth and other
functions [12–16]. BDNF has now been shown to be expressed by sever-
al airway cell types including epithelium, immune cells, nerves and
even ASM [5,17–20]. Furthermore, sputum and/or bronchoalveolar la-
vages (BAL) from patients with asthma, allergic rhinitis or chronic
cough show elevated levels of BDNF [17,21–24] suggesting that the dif-
ferent airway cell typesmay actually secrete BDNF. Here, Kemi et al. [20]
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While secretory mechanisms for BDNF have been examined in neurons,
and involve vesicular release [25], themechanisms underlying BDNF se-
cretion by non-neuronal cells, particularly in the lung, are not clear.
The relevance of understanding BDNF secretion in the airway lies in
the increasing recognition that local growth factor production can
have pleiotropic effects in the context of inﬂammation, especially
given the evidence that a range of airway cells express NT receptors
and can thus respond to local factor production [5].
In neuronal tissues, a major stimulus for NT secretion is elevation in
[Ca2+]i typically following electrical stimulation leading to vesicular re-
lease [26]. While it is likely unnecessary for ASM cells to rapidly secrete
NTs, vesicular secretion pathways do exist in airway cells [27], and are
regulated by a number of complex mechanisms. The mechanisms by
which BDNF release occur in non-neuronal tissues are unknown. The
highly regulated, vesicular release of neurons [25,28] may not be rele-
vant in ASM, and it is beyond the scope of any single study to examine
themany complex secretory pathways thatmay exist in ASM. However,
[Ca2+]i is known to modulate secretion in general, and of BDNF in neu-
rons and vasculature [29,30]. Thus mechanisms that regulate [Ca2+]i in
ASM may play a role in modulating BDNF secretion. In this regard, in
non-ASM cells, recent studies suggest a role for canonical transient recep-
tor potential (TRPC) channels in ﬂuid secretion and in exocytosis of other
intracellular proteins [31].Wehave previously demonstrated that human
ASM expresses a variety of TRPC channels, but TRPC3 is particularly im-
portant for modulating store-operated Ca2+ entry (SOCE) [32]. Relevant
to airway disease, inﬂammatory cytokines such as TNFα increase TRPC3
expression [32,33] while BDNF modulates TRPC3 function in human
ASM [6]. In non-neuronal cells, [34,35] TRPC3 has been shown to regulate
secretion, but its non-SOCE role in ASM is not known. Accordingly, in the
present study, we hypothesized that TRPC3 is important in BDNF secre-
tion by ASM, and tested this hypothesis in human ASM in the context
of enhanced BDNF secretion in the presence of inﬂammation.
2. Material and methods
2.1. Human ASM cells
Previously described techniques for isolating human ASM cells from
lung samples incidental to patient thoracic surgery were used [6,7].
Brieﬂy, under a protocol approved by the Mayo Clinic Institutional
Review Board, surgical lung specimens of patients undergoing
pneumenectomies or lobectomies for focal, non-infectious disease
were obtained from surgical pathology at St. Marys Hospital of the
Mayo Clinic, immediately following diagnosis by the pathologist. To
avoid confounding issues relating to airway pathology, samples were
limited to those from patients without clinical diagnoses of asthma,
COPD or ﬁbrosis. With the pathologist's aid, normal areas of 3rd to 6th
generation bronchi were identiﬁed, dissected free of adventitia, and
placed in cold Hanks' balanced salt solution (HBSS, Invitrogen, Carlsbad,
CA) supplemented with 10 mM HEPES and 2 mM Ca2+. Under micros-
copy, the epithelium was denuded in these bronchial rings, the ASM
layer removed by blunt dissection, minced and ASM cells enzymatically
dissociated. Cells were seeded into culture ﬂasks or other chambers for
experimentation, and maintained under usual culture conditions in
phenol red-free DMEM/F-12 (Invitrogen) supplemented with 10% FBS.
Prior to experimentation, cells were serum starved for 48 h and only
cells of passages 1–3 were used. Maintenance of ASM phenotype with
subculture was veriﬁed as previously described [36] and involved veri-
ﬁcation of smooth muscle actin and myosin but absence of ﬁbroblast
markers (ﬁbroblast surface protein) or epithelial markers (E-cadherin).
2.2. Western analysis
Standard SDS-PAGE (Criterion Gel System; Bio-Rad, Hercules, CA; 4–
15% gradient gels) and PVDF membrane (Bio-Rad) transfer techniqueswere used. Membranes were blocked with milk in TBS with 0.1%
Tween-20 and blotted. GAPDH was used as a loading control. For sec-
ondary antibody detection, either horseradish peroxidase-conjugated
antibodies with chemiluminescence substrate or far-red ﬂuorescent
dye conjugated antibodies were used. Blots were imaged on a Kodak
Image Station 4000MM (Carestream Health, New Haven, CT) or a
LiCor OdysseyXL system, and quantiﬁed using densitometry.
For immunoprecipitation studies of phosphorylated proteins, ASM
cell lysates in RIPA buffer supplementedwith protease inhibitor cocktail
were immunoprecipitated using phosphotyrosine antibody 4G10
(Millipore, 06-427) and immunocomplexes captured using catch re-
lease kit (Millipore, 17–500) per manufacturer instructions. Thereafter,
samples were subjected to SDS-PAGE, PVDF membrane transfer and
immunoblotted against TrkB antibody (Neuromics, GT15080) with
antibody-reactive bands detected as above.
2.3. ELISA
Sandwich ELISA for BDNF in cell supernatants was performed (R&D
Systems, Minneapolis, MN) using standard, manufacturer-provided
protocols. Initial ELISA of undiluted supernatants suggested BDNF levels
at the lower limits of detection of the kit (b20 pg/ml). Therefore, the su-
pernatants were concentrated 12-fold prior to ELISA, and the measure-
ments were corrected post hoc. Colorimetric quantiﬁcation of BDNF
levels was performed on a FlexStation3 microplate reader at 450 nm
(wavelength correction set to 540 nm) and compared to a standard
curve based on manufacturer-supplied recombinant BDNF. Conﬁrma-
tion of BDNF in the supernatant was performed usingWestern analysis
of the same concentrated samples (Millipore Centriprep).
2.4. Pro-inﬂammatory stimulation
Cells made serum-free for at least 24 h were exposed to medium
only, 20 ng/ml TNFα or amixture of allergens (10 μg each of ovalbumin,
and of extracts from Alternaria alternata, Aspergillus fumigatus and
Dermatophagoides farinae (house dust mite)) for 24 h. For inhibition
or siRNA studies, pro-inﬂammatory stimuli followed such interventions.
2.5. siRNA transfection
ASM cells at ~50% conﬂuence were made serum- and antibiotic-free
for 24 h before transfection with 300 pmol of siRNA against TRPC3,
Orai1, STIM1 or caveolin-1 (Ambion-Applied Biosystems, Austin, TX) or
with a HA-tagged TRPC3 overexpression plasmid using Lipofectamine
reagent (Invitrogen, Carlsbad, CA). Scrambled siRNA was used to verify
the lack of off-target effects. Six hours after transfection, fresh growth
mediumwas added and cells were grown overnight. Serum deprivation
was then maintained for 48 h followed by experimentation.
2.6. GFP–BDNF transfection, imaging, and analysis
Serum-free ASM cells at ~50% conﬂuence were transfected with
300 pM of a GFP–BDNF vector [30,37,38] using Lipofectamine reagent.
An empty vector aswell as GFP alonewas used for transfection controls.
Samples were visualized using a Nikon real-time ﬂuorescence imaging
system, with a 100×/1.3 NA oil immersion lens, standard GFP ﬁlters
and a high-sensitivity 14-bit digital camera. GFP–BDNF transfected
cells were exposed to vehicle, TNFα (as above) or Pyr3 and then acutely
exposed to 1 μM of the bronchoconstrictor agent acetylcholine (ACh)
and images were acquired at 1 Hz.
Image analysis was performed using Nikon Elements software. In
image sets of GFP–BDNF transfected ASM cells, peri-membranous re-
gions showing punctate ﬂuorescence were identiﬁed, and small regions
of interest (ROIs)were drawn. At least 10 ROIs that included the plasma
membrane (i.e. covered extracellular and intracellular regions) were
drawn allowing measurements of ﬂuorescence changes representing
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Results).2.7. Materials
BDNF antibody (Abcam rabbit anti TrkB, ab33655); GAPDH antibody
(Cell Signaling mouse anti-GAPDH, #2118); TRPC3 antibody (Alomone,
ACC-016); Orai1 antibody (Alomone, ACC-060); and STIM1 antibody
(Abcam, ab62031) were used. Pyr3 (TRPC3 inhibitor), BAPTA, and
EGTA were obtained from Calbiochem (EMD Chemicals, Gibbstown
NJ) and Xestospongin (IP3R inhibitor) was from Sigma-Aldrich.2.8. Statistical analyses
All experiments were performed in quadruplicate on cells isolated
from 4 different individuals (n = 4). Analysis of the results was accom-
plished using one-way ANOVA with repeated measures or Bonferroni
correction where appropriate. Statistical signiﬁcance was set at
p b 0.05; all values are expressed as means ± SE.Fig. 2. Mechanism of BDNF expression and release in ASM cells. Exposure to TNFα or
mixed allergens signiﬁcantly increased intracellular BDNF expression (Western analysis;
A) as well as its release (B). Inhibition of cyclooxygenase by indomethacin substantially
blunted TNFα enhancement of BDNF expression or release but not that with mixed aller-
gens. Values in bar graph are means ± SE. * indicates signiﬁcant TNFα or mixed allergen
effect, # indicates signiﬁcant inhibitor effect (P b 0.05).3. Results
3.1. BDNF release by human ASM is increased by inﬂammatory stimuli
At baseline, control ASM cells displayed only a small amount of BDNF
in the supernatant, suggestingminimal release. In cells exposed to TNFα,
or particularly tomixed allergens, there was a substantial increase in the
amount of secreted BDNF as detected by ELISA as well as Western anal-
ysis of the supernatant (Fig. 1; p b 0.05 for either stimulation).
While these data demonstrated BDNF secretion, in parallel studies,
Western analysis of ASM cell lysates showed baseline intracellular ex-
pression of BDNF protein that was increased by TNFα and mixed aller-
gens (Fig. 2). Obviously, a number of mechanisms could contribute to
such increases. Based on a previous study suggesting a role for cycloox-
ygenase in BDNF enhancement by cytokines [20], we explored the effect
of indomethacin (10 μM) and found reduced BDNF expression and se-
cretion at baseline as well as with TNFα stimulation (but not with
mixed allergens; Fig. 2; p b 0.05 for indomethacin effect).Fig. 1. Release of brain derived neurotrophic factor (BDNF) by humanairway smoothmus-
cle (ASM) cells. At baseline, only a small amount of BDNFwas detected in the supernatant
of ASM cell cultures. With exposure to 20 ng/ml tumor necrosis factor (TNFα), or partic-
ularly to mixed allergens (see Material and methods for details), there was a substantial
increase in secreted BDNF as detectable by ELISA and Western analysis. Values in bar
graph are means ± SE. * indicates signiﬁcant TNFα or mixed allergen effect (P b 0.05).3.2. Role of TRPC3 in BDNF release
Exposure of ASM cells to TNFα, or particularly to mixed allergens
resulted in a substantial increase in TRPC3 protein expression (Fig. 3;
p b 0.05). siRNA knockdown of TRPC3 also blunted BDNF secretion in
these groups to an extent comparable to Pyr3 (Fig. 3; p b 0.05 for
siRNA effect). siRNA efﬁcacy for TRPC3 knockdown was veriﬁed by
Western analysis (Fig. 3). In contrast, scrambled siRNA for TRPC3 did
not alter its expression, and consistently did not signiﬁcantly inﬂuence
the enhancement of BDNF release by TNFα (Fig. 3). Non-speciﬁc effects
of Pyr3 on TRPC3 expression were also absent. Similarly, pharmacolog-
ical inhibition of TRPC3with 5 μMPyr3 for 24 h substantially decreased
the enhancement of BDNF secretion by TNFα (Fig. 3; p b 0.05 for Pyr3
effect). In contrast to the reduction in BDNF release when TRPC3 was
suppressed, overexpression of TRPC3using theHA-tagged construct en-
hanced baseline BDNF release (Fig. 3; p b 0.05).
In other cell types, BDNF secretion is Ca2+ dependent. A major role
for TRPC3 in human ASM is Ca2+ inﬂux [33,39], while TNFα is known
to increase TRPC3 expression and function [32]. To determine the role
of [Ca2+]i in BDNF release, and the inﬂuence of TRPC3 in this regard,
ASM cells were exposed to vehicle or TNFα and then to one of the fol-
lowing to control [Ca2+]i or its regulation: medium only, 5 μM BAPTA/
AM (to clamp [Ca2+]i), EGTA in zero extracellular Ca2+ (to prevent
Ca2+ inﬂux), or XeC (to inhibit sarcoplasmic reticulum Ca2+ release
via IP3R). Each of these interventions resulted in a signiﬁcant decrease
Fig. 3. Role of canonical transient receptor channel (TRPC3) in BDNF release. In ASM cells,
exposure to TNFα or mixed allergens signiﬁcantly increased TRPC3 expression (A). siRNA
targeting TRPC3 substantially blunted its protein expression, regardless of the inﬂamma-
tory exposure. Scrambled siRNA did not have an inhibitory effect (TNFα exposure
shown). In the presence of TRPC3 siRNA, BDNF secretion by ASM cells was signiﬁcantly
blunted, even in the presence of TNFα or mixed allergens, while scrambled siRNA did
not have an inhibitory effect (B). In contrast, overexpression of TRPC3 using an HA-tagged
construct increased BDNF release (dark gray bar in B). Separately, pharmacological inhibi-
tion of TRPC3 using Pyr3 substantially blunted the enhancing effects of TNFα on BDNF re-
lease. Values in bar graph are means ± SE. * indicates signiﬁcant TNFα or mixed allergen
effect, # indicates signiﬁcant siRNA or Pyr3 effect (P b 0.05).
Fig. 4. Role of [Ca2+]i regulatory mechanisms in BDNF release. ASM cells were exposed to
vehicle or TNFα and then to one of the following to control [Ca2+]i or its regulation:
medium only, 5 μM BAPTA/AM (to clamp [Ca2+]i), EGTA in zero extracellular Ca2+ (to
prevent Ca2+ inﬂux), or Xestospongin C (to inhibit sarcoplasmic reticulum Ca2+ release
via IP3 receptor channels) with or without concurrent Pyr3 inhibition. Each of these inter-
ventions resulted in signiﬁcant decrease in BDNF release albeit to different extents. Values
in bar graph aremeans ± SE. * indicates signiﬁcant TNFα ormixed allergen effect, # indi-
cates signiﬁcant inhibitor effect (P b 0.05).
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TRPC3 with 5 or 10 μM Pyr3 with these interventions had relatively
smaller effect on BDNF release compared to Pyr3 alone (Fig. 4).
Based on the above ﬁndings, BDNF release was visualized and quan-
tiﬁed in GFP–BDNF transfected cells. At baseline, in control ASM cells,
diffuse staining of BDNFwas visible (likely reﬂecting the overexpression
from the vector). However, the cell borders showed areas of punctate
pattern resembling vesicles (Fig. 5). Regions of interest were deﬁned
in these peri-membranous areas to determine changes in GFP–BDNF(Fig. 5B). Following stimulation with 1 μM ACh, peri-membranous
areas with pre-existing punctate ﬂuorescence showed rapid decrease
in ﬂuorescence, while adjacent peri-membranous areas with initially
lower ﬂuorescence showed rapid accumulation of punctate structures
followed bymerging of vesicle-appearing structures with the cell mem-
brane (e.g. see 3rd insets in row of images in Fig. 5A showing effects of
ACh). In cells exposed to TNFα, there was visibly greater baseline
presence of punctate ﬂuorescence at cell borders and a more accelerat-
ed ﬂuorescence reduction as well as accumulation of new ﬂuorescent
areas following ACh stimulation in the continued presence of TNFα
(Fig. 5B). These changes in the different cell groups were reﬂected
by overall ﬂuctuations in ﬂuorescence (Fig. 5). The extent of vesicular
presence or their release by ACh in the presence or absence of TNFα
was substantially blunted by Pyr3 (Fig. 5 shows for non-TNFα exposed
cells) or TRPC3 siRNA (data not shown).
3.3. Role of SOCE in BDNF release
Recent studies, including our own [40,41] have shown that SOCE in
ASM involves the sarcoplasmic reticulum stromal interaction protein
(STIM1) and the plasma membrane protein Orai1. Furthermore, we
have found that Orai1 is present within caveolae of human ASM cells,
and is regulated by the constitutional protein caveolin-1 [40]. Also, in-
ﬂammation increases caveolin-1 and Orai1 expression and function in
ASM [40]. Accordingly, when we examined the contribution of these
mechanisms, we found that siRNA knockdown of STIM1, Orai1 or
caveolin-1 suppressed BDNF release, particularly in the presence of
TNFα (Fig. 6; p b 0.05 for siRNA effects). We have previously demon-
strated the efﬁcacy and speciﬁcity of these siRNAs [40].
3.4. Functional effect of released BDNF
Exogenous BDNF affects ASM [Ca2+]i and cell proliferation largely
via the high-afﬁnity receptor TrkB [6,7,10]. Accordingly, we found in-
creased phosphorylation of TrkB in human ASM, particularly with
TNFα exposure (Fig. 7): effects that were blunted in the presence of
the chimeric protein TrkB-Fc which chelates extracellular BDNF
(Fig. 7; p b 0.05 for TrkB-Fc effect).
4. Discussion
The present study examined the mechanisms by which the
neurotrophin BDNF is secreted by human ASM and found that elevated
Fig. 5. Release of BDNF by human ASM cells. In ASM cells transfected with GFP–BDNF construct, release of BDNF was visualized using time-lapse ﬂuorescence microscopy. Compared to
blank vector transfected cells, GFP–BDNF ﬂuorescencewas visible as a diffuse pattern (likely representing overexpression)with areas of punctate ﬂuorescence near the plasmamembrane
that were largely static in the absence of stimulation (A). Arrows indicate regions enlarged in insets. Stimulation with ACh resulted in rapid changes in peri-membranous ﬂuorescence,
reﬂected by reduced ﬂuorescence in previously bright areas, and increased ﬂuorescence in others (e.g. 3rd row of images and insets in panel A). These data suggest vesicular release of
BDNF with additional contributions of vesicular trafﬁcking. In cells exposed overnight to TNFα, baseline ﬂuorescence and punctate patterns weremore obvious, and the extent of release
was greater following ACh stimulation. These observations were reﬂected by ﬂuorescence measurements within regions of interest (ROIs) in the peri-membranous areas (B; ROIs from
sample ACh exposure series and associated inset). Interestingly, peri-membranous ﬂuorescence changes ﬂuctuated with time (C), with TNFα-exposed cells showing higher levels. Inhi-
bition with Pyr3 prevented changes in ﬂuorescence changes induced by ACh. Values are means + SE. * indicates signiﬁcant TNFα effect (P b 0.05).
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BDNF release, but also in the enhanced secretion of BDNF that occurs
with airway inﬂammation. Furthermore, inﬂammatory stimuli such as
the cytokine TNFα appear to increase BDNF synthesis via mechanisms
such as cyclooxygenase, which may further lead to increased BDNF re-
lease. Given previous studies demonstrating upregulation of airway
BDNF in asthma and allergic diseases, and ﬁndings that BDNF can en-
hance [Ca2+]i, increase cell proliferation and the expression of Ca2+
and force regulatory proteins in ASM, the present study suggests that
ASM itself is a source of local BDNF in the airway and can contribute to
altered structure and function in the presence of airway inﬂammation.
NTs such as BDNF are well-known in the nervous system not only as
growth factors with genomic effects on neuronal development and
function [1–3,15,16], but also for their acute, non-genomic effects suchas enhanced [Ca2+]i and synaptic transmission [42,43]. Interestingly,
NTs can activate several intracellular signaling cascades such as phos-
phatidylinositol 3 kinase (PI3K), and mitogen activated protein kinases
(MAPKs) [12–14] which are also important for mediating the effects of
inﬂammatory cytokines such as TNFα, that are known to be involved in
airwaydiseases. Accordingly, the increasing evidence that NTs including
BDNF, and their receptors (particularly the Trks) are expressed in the
lung [5] becomes signiﬁcant. For example, we previously reported that
the BDNF/TrkB system is present and functions in human ASM cells
[6,7] such that on the one hand BDNF non-genomically enhances
[Ca2+]i responses to agonist [7] and potentiates the effects of TNFα [6]
and on the other it genomically enhances expression of [Ca2+]i and
forces regulatory proteins [11] and ASM cell proliferation [10]. While
these studies demonstrate that human ASM responds to BDNF
Fig. 6. Role of store-operated Ca2+ entry (SOCE)mechanisms in BDNF secretion. siRNA in-
hibition of the expression of the SOCE mechanisms STIM1 and Orai1 both blunted BDNF
secretion in ASM cells, especially in the presence of TNFα. Separately, siRNA suppression
of the plasma membrane caveolar protein caveolin-1, which harbors the Orai1 protein
(as well as TRPC3) also, prevented BDNF release, albeit not to the same extent. Values
are means + SE. * indicates signiﬁcant TNFα effect, # indicates signiﬁcant siRNA effect
(P b 0.05).
2958 P.K. Vohra et al. / Biochimica et Biophysica Acta 1833 (2013) 2953–2960regardless of its source, the novelty of the present study lies in the dem-
onstration that ASM is also a source of BDNF that can be modulated in
the setting of inﬂammation.
Previous studies have shown that airway cells such as epithelium,
ASM, immune cells, and nerves, are all capable of producing BDNF
[5,17–20]. The relevance of such effects lies in the recent recognition
that circulating BDNF levels as well as local receptor expression are in-
creased in asthma [5,17]. Clinical ﬁndings suggest increased NT levels
in both sputum and bronchoalveolar lavages of patientswith chronic in-
ﬂammatory airway diseases associated with smoking and with smoke
exposure [22,44]. While these studies associate airway disease with
elevated BDNF, the question remains as to the source of BDNF and the
functional relevance of elevated BDNF. In this regard, NTs derived
from airway nerves have been suggested as contributing to neurogenic
asthma while those by immune cells are thought to modulate inﬂam-
mation [17,45] and thus may be upregulated by environmental factors
including inﬂammation itself. Cytokines (e.g. TNFα)may then indirectly
upregulate NT expression and signaling. For example, we have previ-
ously shown that TNFα enhances BDNF and TrkB expression in human
ASM [6] while Kemi et al. noted increases in different NTs (including
BDNF) following stimulation with other cytokines, particularly IL-1β
[20]. Functional studies in animals suggest a role for BDNF in airway in-
ﬂammation, remodeling, and hyperreactivity [46,47]. The present studyFig. 7. Functional effect of BDNF. Immunoprecipitation of the phosphorylated form of
the high-afﬁnity BDNF receptor TrkB demonstrated that the secreted BDNF had autocrine
effects on ASM. Such effects were blunted by the extracellular BDNF chelator TrkB-Fc
(chimeric Fc portion of the TrkB receptor), but enhanced by exogenous, recombinant
human BDNF as well as by the enhanced secretion induced by TNFα or allergens. Values
are means + SE. * indicates signiﬁcant TNFα or allergen effect, # indicates exogenous
BDNF effect, % indicates TrkB-Fc effect (P b 0.05).now provides novel data demonstrating potential mechanisms by
which such BDNF enhancement may occur, and the fact that it may
not be just BDNF expression, but its secretion into the extracellular en-
vironment. Here, inﬂammation enhancement of BNDF may involve in-
creased synthesis via mechanisms of interest to airway disease such as
cyclooxygenase as demonstrated in the present study, and consistent
with previous data [20]. Accordingly, given the expression of BDNF
receptors in epithelium, ASM, nerves and immune cells [48] ASM-
derived BDNF can potentially have autocrine/paracrine effects in the air-
way that mediate the functional effects of inﬂammation such as airway
hyperresponsiveness and remodeling/cell proliferation. In this regard,
the present ﬁndings that chelation of secreted BDNF via the chimeric
protein TrkB-Fc (thus competing with cell surface TrkB receptors) pre-
vents TrkB phosphorylation within ASM cells suggest at least an auto-
crine target for secreted BDNF. Whether this occurs in vivo remains to
be determined.
A major, novel ﬁnding of the current study is the importance of
TRPC3 and [Ca2+]i in BDNF secretion by ASM, particularly in the
presence of inﬂammation. Compared to relatively detailed examination
of TRPCs in the vascular smooth muscle, less is known regarding TRPCs
in the normal function of the airway, or in respiratory diseases. None-
theless, previous studies have examined TRPC isoforms in ASM, and
their potential involvement in diseases such as asthma and COPD
[33,49–55]. Studies in ASM of multiple species including humans all
show expression of TRPC1, TRPC3, TRPC4, TRPC5, TRPC6 and TRPC7 al-
beit to different levels [32,56–60]. However, a majority of functional
studies have focused on TRPC3 which is themajor component of native
non-selective cation channels and thus contributes to elevation of
[Ca2+]i in response to agonist stimulation and with store depletion
[33,39]. Limited data demonstrate that TRPC3 regulates resting mem-
brane potential in ASM, such that siRNA knockdown of TRPC3 lowers
membrane potential [33,39]. Importantly, TRPC3 is involved in [Ca2+]i
responses to agonists such as ACh [32,33] where in addition to allowing
Ca2+ entry, TRPC3may alsomodulate local [Ca2+]i levels in the proxim-
ity of theplasmamembrane, thus inﬂuencing othermechanisms such as
Na+/Ca2+ exchange or membrane potential which then enhance inﬂux
via L-type Ca2+ channels [61]. In this regard, a recent discovery has been
that TRPC3 localizes to caveolae in human ASM [40,62]. In turn,we have
reported that caveolin-1, the constitutive scaffolding protein within
caveolae regulates TRPC3 function in terms of Ca2+ inﬂux [62]. Accord-
ingly, the relevance of TRPC3 regulation of BDNF release lies in the fact
that TRPC3 can regulate both store- and receptor-operatedmechanisms
to maintain inﬂux over sustained periods following agonist stimulation
and thus substantial enhance BDNF release, particularly in the presence
of inﬂammation.
Given themultiple effects of TRPC3, previous studies have examined
the importance of altered TRPC3 expression and function in airway dis-
eases. For example, increased TRPC3 expression occurs in airways of
patients with asthma [33,39,63]. Separately, we have shown that
TNFα upregulates TRPC3 expression in humanASM [32] and functional-
ly contributes to TNFα-induced enhancement of [Ca2+]i and thus air-
way contractility [32]. Accordingly, the ﬁndings in our present study
that enhanced TRPC3 expression occurswith TNFα exposure are consis-
tent. However, more importantly, such enhanced TRPC3 appears to be
important for the increase in BDNF secretion observed not only in the
presence of TNFα but also with a more generalized inﬂammatory stim-
ulus induced bymixed allergens that likely activate a number of cell sur-
face receptors important in airway diseases such as asthma. Here, the
role of toll-like receptors (TLRs) is likely, given the fungal allergens
used in the present study. Indeed as part of the present study, we
found both TLR2 and TLR4 to be expressed by human ASM cells and in
fact upregulated by mixed allergen exposure (Supplemental ﬁgure).
Whether TLRs act through TRPC3 to induce BDNF release is not known
and should be examined in future studies. Overall, the present data sug-
gest a strong link between airway inﬂammation, TRPC3 and enhanced
BDNF release.
2959P.K. Vohra et al. / Biochimica et Biophysica Acta 1833 (2013) 2953–2960In addition to TRPC3 per se, elevated [Ca2+]i seems to be a key player
in BDNF release by ASM. In some respect, a role for [Ca2+]i in secretory
mechanisms is to be expected. However, secretion of growth factors via
presumably a vesicularmechanism (suggested by the real-time imaging
of GFP–BDNF) has not been previously shown in human ASM. Here, the
observation that peri-membranous GFP–BDNF occurs at baseline and
decreaseswith ACh stimulation is reﬂective of vesicular release. Howev-
er, what is also interesting is the ﬁnding that other peri-membranous
areas with low ﬂuorescence at baseline subsequently demonstrate in-
creased ﬂuorescent aggregates followed by such vesicular release.
These complementary observations are highly suggestive of ongoing
vesicular release as well as trafﬁcking during agonist stimulation. Fur-
thermore, the observation that baseline vesicular BDNF is higher in
ASM cells with TNFα exposure, as are the amplitudes of ﬂuorescence
changes, suggests that inﬂammation “primes” ASM for BDNF release
with agonist stimulation. Accordingly, via this mechanism, enhanced
BDNF secretionmay contribute to the functional effects of inﬂammation
on airway tone, for example. What remain to be determined in future
studies are the mechanisms underlying vesicle release vs. trafﬁcking
in ASM, a largely unexplored area.
The link between [Ca2+]i and BDNF secretion appears to also involve
other regulatory mechanisms. In ASM, [Ca2+]i regulation involves sar-
coplasmic reticulum Ca2+ release via IP3R [64] and RyR channels [65]
as well as Ca2+ inﬂux via voltage-gated channels [66], receptor-gated
channels [67,68] and SOCE in response to intracellular Ca2+ depletion
[60,69]. In this regard, recent studies, including our own have highlight-
ed the importance of STIM1 and Orai1 in SOCE, with the additional in-
volvement of caveolae and caveolin-1 [40]. Importantly, inﬂammation
appears to increase the expression and function of these proteins in
ASM [40]. Accordingly, the results of the present study showing reduced
BDNF release, particularly in inﬂammation, when STIM1, Orai1 or
caveolin-1 are knocked down by siRNA, all demonstrate the importance
of SOCE in modulation of BDNF release. In addition, TRPC3 can also reg-
ulate gene expression via multiple signaling intermediates, particularly
the Ca2+–calcineurin–NFAT and Ca2+–CaMK pathways [70]. These al-
ternative scenarios remain to be tested in the context of BDNF release
by ASM.
The phosphorylation of TrkB and its suppression by the extracellular
BDNF chelator shown in the present study demonstrates the autocrine/
paracrine capability of ASM-derived BDNF. Accordingly, not only is ASM
a local source of BDNF in the airway, but a potential target aswell. In this
regard, the link between BDNF and TRPC3 and/or SOCEmay be of inter-
est in an additional manner. As shown in previous studies, exogenous
BDNF can directly inﬂuence ASM [Ca2+]i [7]. In neurons, BDNF increases
Ca2+ release from intracellular stores [71–73] via the phospholipase C/
IP3/IP3R pathway [74]. We previously found that BDNF enhances
[Ca2+]i via IP3R channels in human ASM [7]. In pontine neurons, BDNF
increases Ca2+ inﬂux via TRPC3 channels [75]. We recently reported
that BDNF does enhance SOCE in human ASM as well [11] although a
role for TRPC3 or STIM/Orai1 has not been speciﬁcally established.
Nonetheless, we recently reported that with prolonged exposure,
BDNF can enhance the expression of IP3R and Orai1 [11]. Accordingly,
it is possible that the initial increase in BDNF release induced by agonist
stimulation, for example, or by inﬂammation, can produce autocrine ef-
fects of further enhancing TRPC3 function or SOCE, thus sustaining
BDNF release. This interesting scenario may be important in that early
interferencewith BDNF, for example by chelatingwith TrkB-Fc, may in-
terrupt the vicious cycle of elevated [Ca2+]I, release of a pro-contractile
growth factor, and downstream genomic effects that contribute to air-
way hyperresponsiveness and remodeling.
4.1. Conclusions
In conclusion, the present study demonstrates that even non-
neuronal tissues such as human ASM actively secrete BDNF, and that
inﬂammatory conditions can stimulate such BDNF production andsecretion by enhancing speciﬁc signaling pathways including plasma
membrane Ca2+ regulatory mechanisms. The implications of BDNF re-
lease by ASM cells lies in the recently recognized pro-contractile and
pro-proliferative roles of this neurotrophin that may contribute to al-
tered airway structure and function that exists in allergic airway dis-
eases including asthma.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2013.07.019.
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